The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open-label phase 1 dose-escalation and dose-expansion trial to evaluate the safety, tolerability, and efficacy of TQ-B3234 in adults with neurofibromatosis type 1 (NF1).
 
Jun Liu
No Relationships to Disclose
 
Qingfeng Li
No Relationships to Disclose
 
Zhichao Wang
No Relationships to Disclose
 
Jingxuan Huang
No Relationships to Disclose
 
Weiqin Tang
No Relationships to Disclose
 
Wei Wang
No Relationships to Disclose
 
Yihui Gu
No Relationships to Disclose
 
Chengjiang Wei
No Relationships to Disclose
 
Jian Jin
No Relationships to Disclose
 
Jianxia Meng
No Relationships to Disclose
 
Shijie Zhong
No Relationships to Disclose
 
Xunqiang Wang
Employment - Chia Tai Tianqing Pharmaceutical Group Co.Ltd.
 
Wenwen Hu
Employment - Chia Tai Tianqing Pharmaceutical Group Co.Ltd.
 
Bin Hu
Employment - Chia Tai Tianqing Pharmaceutical Group Co.Ltd.
 
Xiaojing Wan
Employment - Chia Tai Tianqing Pharmaceutical Group Co.Ltd.